Lenalidomide Zentiva

Lenalidomide, the active ingredient in Lenalidomide Zentiva, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in combination therapy. GNH USA supplies Lenalidomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that rely on abnormal plasma‑cell or marrow proliferation. - Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle cell lymphoma (in combination therapy): enhances response when added to standard chemo‑immunotherapy regimens.

Adverse reactions vary in frequency and severity. Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count leading to easy bruising. - Anemia: decreased red blood cells causing weakness. - Diarrhea: loose stools that may require hydration. - Rash: mild skin irritation or redness. Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound infection susceptibility. - Severe thrombocytopenia: significant bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions.

Patients should be monitored closely for safety concerns before and during therapy. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Thromboembolic risk assessment: evaluate for clotting risk and consider prophylaxis. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Renal function adjustment: modify dose in patients with impaired renal clearance. - Drug interaction review: assess concomitant medications for potential interactions. - Store below 25°C: keep in the original container, protect from moisture and light.

Lenalidomide may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. Moderate Interactions (Monitor Closely): - NSAIDs: additive risk of gastrointestinal bleeding. - CYP2C19 inhibitors (e.g., fluconazole): may modestly raise exposure. - Live vaccines: immunosuppression can diminish vaccine effectiveness.